HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
-
BUSINESS 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
-
BUSINESS FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
-
REGULATORY G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
-
BUSINESS Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
-
REGULATORY LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
-
BUSINESS Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
-
REGULATORY LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
-
BUSINESS Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
-
REGULATORY Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
-
BUSINESS Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
-
BUSINESS Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
-
REGULATORY Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
-
ACADEMIA Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
-
REGULATORY Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
REGULATORY Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
BUSINESS 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
-
ACADEMIA More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
-
BUSINESS Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…